Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Burkholderia cepacia infections in cystic fibrosis are caused by a group of bacteria that can infect the lungs of people with cystic fibrosis (CF), a genetic disorder affecting the respiratory system. These infections mainly affect the lungs, leading to worsening breathing problems and lung damage. The bacteria are resistant to many common antibiotics, making infections difficult to treat. People with CF who get this infection may experience more frequent lung infections and a faster decline in lung function. The infection can spread between individuals with CF, so it is a serious concern in this population. Early detection and careful management are important to control symptoms and prevent complications.

Clinical Definition

Burkholderia cepacia complex (Bcc) comprises related opportunistic, aerobic, nonfermenting gram-negative bacilli. In CF, dehydrated mucus and impaired clearance permit persistent airway infection. Outcomes range from little additional deterioration to progressive lung disease or cepacia syndrome, rapidly progressive pneumonia with bacteremia/sepsis. Risk differs by species and strain; B. cenocepacia is especially concerning. Resistant infection can complicate transplantation, but Bcc positivity is not a universal exclusion.

Inciting Event

  • Inhalation or aspiration of B. cepacia from contaminated environmental sources or patient-to-patient transmission initiates infection.

  • Person-to-person spread can occur in health-care or social settings; environmental acquisition also occurs and the source is often unknown.

  • Antibiotic exposure can alter airway ecology and select resistant organisms, but it is not a required or proven single trigger of Bcc acquisition.

Latency Period

  • There is no fixed incubation or latency interval for CF airway acquisition; detection and clinical deterioration may be widely separated.

  • Chronic colonization may be asymptomatic for prolonged periods before clinical deterioration occurs.

  • Cepacia syndrome can evolve rapidly after acquisition or during established infection; it is not confined to the first days or weeks.

Diagnostic Delay

  • Misidentification of B. cepacia complex due to its phenotypic similarity to other gram-negative rods delays diagnosis.

  • Low clinical suspicion in early colonization leads to underdiagnosis in cystic fibrosis patients.

  • Inadequate or infrequent sputum cultures may miss intermittent shedding of B. cepacia.

  • Delayed recognition of cepacia syndrome due to nonspecific symptoms and overlap with cystic fibrosis exacerbations.

Clinical Presentation


Signs & Symptoms

  • Chronic productive cough with purulent sputum

  • Recurrent pulmonary infections and exacerbations of respiratory symptoms

  • Fever and malaise during acute infection

  • Increased dyspnea and exercise intolerance

  • Weight loss and failure to thrive in advanced disease

History of Present Illness

  • Progressive cough and increased sputum production are common initial symptoms in B. cepacia infection.

  • Recurrent pulmonary exacerbations with fever and malaise often signal worsening infection.

  • Rapid decline in lung function and development of necrotizing pneumonia characterize cepacia syndrome.

  • Systemic symptoms such as weight loss and fatigue may develop with chronic infection.

Past Medical History

  • Known cystic fibrosis diagnosis with prior chronic lung infections is the primary relevant history.

  • Document prior airway organisms and therapies; Pseudomonas coinfection is common in CF but does not itself establish the cause of Bcc acquisition.

  • History of frequent antibiotic courses and hospitalizations for pulmonary exacerbations.

  • Prior lung transplantation may predispose to invasive B. cepacia infection.

Family History

  • CF is autosomal recessive due to CFTR variants; family history informs susceptibility, while Bcc infection itself is acquired.

  • Inherited susceptibility also occurs in CGD, with X-linked or autosomal recessive phagocyte oxidase defects; susceptibility is not restricted to CF.

  • Shared household exposures and inherited host factors may both matter; familial clustering does not prove direct bacterial inheritance.

Physical Exam Findings

  • Crackles and wheezing on lung auscultation indicating airway inflammation

  • Digital clubbing can accompany chronic CF lung disease; it is not specific for Bcc or a direct measure of current oxygen saturation.

  • Tachypnea and increased work of breathing during acute infection

  • Cyanosis in severe respiratory compromise

  • Decreased breath sounds in areas of lung consolidation or collapse

Diagnostic Workup


Diagnostic Criteria

Detect Bcc in respiratory culture using suitable selective media, then confirm identification with a laboratory experienced in CF organisms, often using molecular methods. Species-level identification has prognostic and infection-control value. A positive culture establishes organism recovery, not necessarily the cause of an acute exacerbation. Interpret symptoms, spirometry and imaging together. Bcc susceptibility testing is problematic: CLSI withdrew clinical breakpoints, so involve microbiology/infectious-disease specialists rather than treating a routine susceptible label as definitive.

Pathophysiology


Key Mechanisms

  • Chronic pulmonary colonization by Burkholderia cepacia complex leads to persistent airway inflammation and progressive lung damage in cystic fibrosis.

  • Biofilm formation by B. cepacia enhances resistance to antibiotics and host immune defenses, promoting chronic infection.

  • Endotoxin release from B. cepacia triggers intense neutrophilic inflammation and tissue injury in the lungs.

  • Multidrug resistance mechanisms in B. cepacia complicate eradication and contribute to treatment failure.

  • Epithelial cell invasion by B. cepacia facilitates persistence and dissemination within the respiratory tract.

InvolvementDetails
Organs

Lungs are the main organ affected, with chronic infection causing bronchiectasis and respiratory failure.

Sinuses may serve as reservoirs for persistent infection in cystic fibrosis patients.

Tissues

Pulmonary tissue is the primary site of infection and inflammation leading to progressive lung damage.

Mucosal tissue in the airways is disrupted by chronic colonization and biofilm formation.

Cells

Neutrophils play a central role in the inflammatory response to Burkholderia cepacia infection in cystic fibrosis lungs.

Macrophages contribute to bacterial clearance and cytokine production during infection.

Epithelial cells of the respiratory tract are damaged by chronic infection and inflammation.

Chemical Mediators

Interleukin-8 (IL-8) is elevated and recruits neutrophils to the site of infection.

Tumor necrosis factor-alpha (TNF-α) mediates inflammation and tissue damage in infected lungs.

Reactive oxygen species (ROS) produced by neutrophils contribute to bacterial killing and lung injury.

Treatments


Pharmacological Treatments

  • Ceftazidime

    • Mechanism:
      • Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins

    • Side effects:
      • Allergic reactions

      • Gastrointestinal upset

      • Neurotoxicity, including encephalopathy or seizures, particularly with accumulation in renal impairment; adjust dosing to renal function.

    • Clinical role:
      • Potential component of an individualized regimen; not universally first-line. Selection considers prior response, species, infection severity and laboratory limitations, often with combination therapy for severe disease.

  • Trimethoprim-sulfamethoxazole

    • Mechanism:
      • Inhibits sequential steps in bacterial folate synthesis, leading to bactericidal activity

    • Side effects:
      • Rash

      • Hyperkalemia

      • Bone marrow suppression

    • Clinical role:
      • Commonly considered treatment option when appropriate, with specialist selection and monitoring; resistance and intolerance preclude a universal first-line rule.

  • Meropenem

    • Mechanism:
      • Binds to penicillin-binding proteins, inhibiting bacterial cell wall synthesis

    • Side effects:
      • Seizures

      • Hypersensitivity reactions

      • Gastrointestinal upset

    • Clinical role:
      • Potential intravenous component of a specialist regimen; activity varies and no fixed second-line ranking applies to all Bcc infections.

  • Tobramycin

    • Mechanism:
      • Binds to 30S ribosomal subunit, inhibiting bacterial protein synthesis

    • Side effects:
      • Nephrotoxicity

      • Ototoxicity

      • Neuromuscular blockade

    • Clinical role:
      • Not a routine Bcc treatment because aminoglycoside resistance is common/intrinsic. Inhaled tobramycin may target coexisting Pseudomonas; exceptional Bcc use needs specialist justification.

Non-pharmacological Treatments

  • Regular airway clearance techniques including chest physiotherapy to improve mucus clearance.

  • Strict infection control measures to prevent cross-infection among cystic fibrosis patients.

  • Nutritional support to maintain optimal body weight and immune function.

Prevention


Pharmacological Prevention

  • Routine chronic antibiotic suppression for stable Bcc infection has no established effective regimen; specialist decisions should not be copied automatically from Pseudomonas care.

  • Inhaled tobramycin is not established Bcc prophylaxis. Use for a separate documented indication, such as Pseudomonas, should be distinguished from treating Bcc.

  • New Bcc acquisition or a pulmonary exacerbation warrants prompt CF/infectious-disease consultation for an individualized, often combined antibiotic regimen; this is treatment, not primary prevention.

  • Mucus-directed CF therapy supports airway clearance and lung health but does not reliably prevent or eradicate Bcc infection.

  • Use antimicrobial stewardship to avoid unnecessary exposure while promptly treating clinically significant infection; broad-spectrum therapy may be necessary for severe disease.

Non-pharmacological Prevention

  • Follow CF infection-control measures: hand hygiene, appropriate contact precautions and separation of people with CF by at least six feet, except members of the same household.

  • Regular airway clearance techniques such as chest physiotherapy

  • Routine sputum surveillance cultures to detect early colonization

  • Clean and disinfect respiratory equipment correctly, do not share it, and follow warnings about contaminated products. Avoiding all hospitals or all water exposure is neither practical nor the prevention goal.

  • Nutritional support to maintain immune function and lung health

Outcome & Complications


Complications

  • Cepacia syndrome, a rapidly progressive necrotizing pneumonia with sepsis

  • Respiratory failure due to progressive lung damage

  • Post-transplant recurrent/invasive infection and mortality are major concerns, especially with B. cenocepacia; do not equate this with proven increased graft rejection from every Bcc species.

  • Multidrug-resistant infections complicating treatment

  • Chronic inflammation leading to bronchiectasis progression

Short-term Sequelae Long-term Sequelae
  • Acute pulmonary exacerbations with worsening cough and hypoxia

  • Sepsis and systemic inflammatory response in severe infections

  • Hospitalization for intravenous antibiotics and respiratory support

  • Transient decline in lung function measured by spirometry

  • Increased sputum production and airway obstruction

  • Progressive decline in pulmonary function leading to chronic respiratory failure

  • Development of chronic multidrug-resistant Burkholderia cepacia colonization

  • Mortality risk varies by species, strain, underlying lung disease and clinical course; not every Bcc acquisition causes rapid decline.

  • End-stage lung disease may prompt transplant assessment. Species-level identification matters; B. cenocepacia requires experienced-center risk assessment rather than a blanket rule for all Bcc.

  • Persistent bronchiectasis and airway remodeling

Differential Diagnoses


Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Pseudomonas aeruginosa Infection

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia)

Pseudomonas aeruginosa Infection

Aerobic nonfermenting gram-negative bacilli; pigmentation and oxidase reactions vary. Reliable laboratory identification distinguishes Bcc species.

Nonfermenting gram-negative rod often producing blue-green pigment and characteristic odor, but these features may be absent and do not replace identification.

Often resistant to aminoglycosides and polymyxins; specialist regimens account for substantial susceptibility-testing limitations.

Resistance to antipseudomonal beta-lactams and aminoglycosides is common in chronic CF infection; select treatment using microbiology and clinical response.

May remain stable, cause chronic decline or produce rapidly progressive cepacia syndrome.

May cause chronic infection or acute severe exacerbation; tempo alone cannot identify the pathogen.

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Staphylococcus aureus Infection

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia)

Staphylococcus aureus Infection

Gram-negative bacilli, usually oxidase-positive but reactions vary by species.

Gram-positive cocci in clusters; S. aureus is catalase- and coagulase-positive.

More frequent in older children and adults with cystic fibrosis

Common in young children with cystic fibrosis

Requires individualized Bcc-directed therapy; no uniform effective regimen.

Treatment depends on methicillin susceptibility and infection site: anti-staphylococcal beta-lactams for MSSA, MRSA-active agents when indicated.

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Non-tuberculous Mycobacterial (NTM) Infection

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia)

Non-tuberculous Mycobacterial (NTM) Infection

Non-acid-fast gram-negative organisms identified on appropriate bacterial cultures.

Mycobacterial cultures and species identification are important; AFB smear can be negative. NTM lung disease requires compatible symptoms/imaging plus microbiologic criteria.

Can be chronic or rapidly progressive; cepacia syndrome is the fulminant form.

Variable course with nodular/bronchiectatic or cavitary patterns; some isolates represent airway presence without progressive NTM disease.

Specialist antibiotics are selected for clinical infection; combinations are often used in severe disease.

When NTM pulmonary disease warrants treatment, use a prolonged species-specific multidrug regimen; a single positive culture does not automatically require therapy.

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Aspergillus fumigatus Colonization or Infection

Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia)

Aspergillus fumigatus Colonization or Infection

Gram-negative bacterial rods on culture

Fungal hyphae seen on microscopy and culture

Neutrophilic inflammation is typical, but eosinophilia or coexisting ABPA is possible.

Aspergillus colonization does not equal ABPA. Allergic disease may cause high total/specific IgE and eosinophilia; invasive disease is a different syndrome.

Bcc culture can coexist with fungal sensitization or infection; negative fungal serology is not a Bcc diagnostic criterion.

ABPA requires compatible clinical/imaging findings plus fungal sensitization and elevated total IgE with additional supportive evidence; serology alone does not define all Aspergillus disease.